Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Policy / Regulatory

Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability

Fineline Cube Aug 29, 2024

JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...

Company Legal / IP

China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation

Fineline Cube Aug 29, 2024

BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...

Company Deals

Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases

Fineline Cube Aug 29, 2024

NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...

Company Deals

Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit

Fineline Cube Aug 29, 2024

LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...

Company Drug

Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines

Fineline Cube Aug 29, 2024

BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...

Company Drug

Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study

Fineline Cube Aug 29, 2024

JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096),...

Company Drug

Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study

Fineline Cube Aug 29, 2024

HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced...

Company Deals

Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development

Fineline Cube Aug 29, 2024

CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...

Company Medical Device

Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China

Fineline Cube Aug 29, 2024

NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...

Policy / Regulatory

China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety

Fineline Cube Aug 29, 2024

BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...

Company

Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs

Fineline Cube Aug 29, 2024

Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech

Fineline Cube Aug 29, 2024

Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347)...

Company

Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues

Fineline Cube Aug 29, 2024

Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...

Company

Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report

Fineline Cube Aug 29, 2024

Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...

Company

Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments

Fineline Cube Aug 29, 2024

Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first...

Company Drug

Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China

Fineline Cube Aug 28, 2024

Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...

Company

AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion

Fineline Cube Aug 28, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to...

Company Deals

Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China

Fineline Cube Aug 28, 2024

Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...

Company Drug

Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns

Fineline Cube Aug 28, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...

Company Deals

Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million

Fineline Cube Aug 28, 2024

Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...

Posts pagination

1 … 297 298 299 … 657

Recent updates

  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.